Allergan PLC. (NYSE:AGN) was downgraded by equities research analysts at Mizuho from a “buy” rating to a “neutral” rating in a note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $193.00 price target on the stock. Mizuho’s price target points to a potential upside of 2.51% from the company’s previous close.

AGN has been the subject of several other reports. Citigroup Inc. reissued a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a research note on Wednesday, September 20th. Piper Jaffray Companies set a $227.00 price target on Allergan PLC. and gave the stock a “hold” rating in a report on Friday, October 6th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a report on Wednesday, September 6th. Deutsche Bank AG set a $251.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Tuesday, October 17th. Finally, Wells Fargo & Company set a $276.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $252.39.

Shares of Allergan PLC. (AGN) traded down 0.52% during midday trading on Thursday, hitting $188.28. The company had a trading volume of 4,755,555 shares. The firm has a market capitalization of $62.94 billion, a PE ratio of 5.74 and a beta of 1.15. Allergan PLC. has a 12 month low of $182.80 and a 12 month high of $256.80. The company has a 50-day moving average of $211.30 and a 200 day moving average of $230.36.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period in the previous year, the firm posted $3.35 EPS. Allergan PLC.’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, analysts expect that Allergan PLC. will post $16.21 EPS for the current fiscal year.

Allergan PLC. declared that its Board of Directors has initiated a stock buyback plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION WARNING: “Mizuho Downgrades Allergan PLC. (AGN) to Neutral” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/22/mizuho-downgrades-allergan-plc-agn-to-neutral.html.

A number of hedge funds have recently modified their holdings of the stock. Hudock Capital Group LLC increased its position in Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after acquiring an additional 2 shares during the period. GWM Advisors LLC increased its position in Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after acquiring an additional 5 shares during the period. Burns J W & Co. Inc. NY increased its position in Allergan PLC. by 0.7% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after acquiring an additional 6 shares during the period. Pacific Center for Financial Services increased its position in Allergan PLC. by 1.3% in the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after acquiring an additional 7 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC increased its position in Allergan PLC. by 0.5% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after acquiring an additional 9 shares during the period. Hedge funds and other institutional investors own 81.94% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.